Coridon Pty Ltd

  Overview

Coridon is a startup biotech company headquartered in Brisbane, Australia. As the worldwide licensee of intellectual property relating to codon optimization, including a granted US patent, it has exclusive access to a novel and generic platform technology, Coricode©, which will build a pipeline of products and services for the company including novel polynucleotide prophylactic/therapeutic vaccines and cancer therapeutic treatments.

  Competitive Advantages

Coridon’s business is centred around predicting and optimising the appropriate commercial choice of codons in polynucleotides in order to promote or restrict expression of polynucleotides in specific mammalian cell types, tissues or state of cell differentiation. This effect can be engineered by polynucleotide design to be much larger in magnitude than is observed with tissue-specific promoters. Coridon does not use human consensus preferred codons. We design synthetic polynucleotides that are differentially expressed in the target cell of choice, in order to generate novel preventive and therapeutic products.

  Technology

Coricode© is based on the observation by Dr Ian Frazer at Centre for Immunology and Cancer Research at The University of Queensland, that protein expression in a mammalian cell type e.g. a skin keratinocyte can be optimised by delivering a polynucleotide created to optimise translational efficiency in that cell type and not other cell types. A set of novel constructs, the Coricode© constructs, are used to determine translational efficiency in the cell type of interest.

  Corporate Alliances/Partnerships

Coridon has existing corporate alliances in the fields of CHO cell fermentation, polynucleotide vaccines and cancer therapeutics.

Partners

Coricode© for CHO cell fermentation is now available for licensing, in order to create proprietary synthetic polynucleotides to enhance the efficiency of your recombinant protein production. Coridon also provides a service to determine a specific Coricode© for your cell types of interest.

Partnering Needs

Coridon is developing a pipeline of next generation polynucleotide vaccines and a topical polynucleotide treatment for squamous cell carcinoma. As part of its development program it seeks collaborative alliances in these areas

Contact Person	Janet Caffin
Job Title	Director Business Development
Address	Coridon Level 2, Research Extension Building 1 PA Hospital
City/Suburb	PO Box 6132 Buranda QLD 4102 Australia
Email	j.caffin@coridon.com
Phone	+61 7 3240 5280
Fax	+61 7 3240 5310
Website Address	www.coridon.com

back